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1 Introduction
Conjugated linoleic acid (CLA) is the name given to a set 
of geometrical and position isomers of the octadecadienoic acid 
with predominance (70-80%) of the cis-9, trans-11 and trans-10, 
and cis-12 isomers (PARODI, 1977; OUSTROWSKA et al., 2004). 
CLA can be synthesized by ruminants by biohydrogenation of 
dietary unsaturated fatty acids or endogenously in the mammary 
glands. Since the late 1970s, when CLA was discovered, its 
consumption has been associated with physiological effects such 
as body fat reduction, arteriosclerosis reduction, prevention 
and treatment of type 2 diabetes mellitus, enhancement of bone 
mineralization, immune system modulation, antithrombogenic 
action, and antioxidant action (SALAS-SALVADÓ; MARQUEZ-
SANDOVAL; BULLÓ, 2006; PARIZA  et  al., 1979; PARIZA; 
HARGRAVES, 1985). However, there has also been significant 
investigation about the possibility of adverse effects of CLA 
consumption, particularly regarding increased susceptibility 
to biological lipid oxidation, resistance to insulin, and lipid 
accumulation in the liver; the latter can be one of the causes of 
non-alcoholic steatosis and steatohepatitis (YAMASAKI et al., 
2000; BASU; SMEDMAN; VESSBY, 2000; RISÉRUS  et  al., 
2004; CHOI; SONG, 2005; BROWN; MCINTOSH, 2003). 
This hypothesis was raised because CLA can act as a ligand of 
peroxisome proliferator activated receptors (PPAR) and inhibit 
their gene expression, particularly PPAR γ (BELURY et al., 2002; 
KANG et al., 2003). Studies show that inhibition of PPAR γ 
and also of PPAR α is related to the possibility of development 
of non-alcoholic steatohepatitis. Furthermore, some authors 
reported, based on biological assays with different experimental 
models, that CLA can lead to changes including not only lipid 
accumulation, but also significant lesions in liver cell organelles 
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2.4 Supplementation
Animals were supplemented by orogastric intubation with 
disposable 1 mL syringes and gavage needles. The amount 
of supplement administered was computed every other day 
according to the average daily feed consumption of each group, 
i.e., supplementation followed the normal feed ingestion. The 
quantity, in milliliters, of each supplement was calculated 
considering the density of the supplements (linoleic acid: 
0.90  g.mL-1; AdvantEdge®CLA: 0.87 g.mL-1; and CLA One®: 
0.77 g.ml-1) and ranged from 0.25 to 0.49 mL. During the 
experimental procedures, the supplements were kept away from 
light to avoid oxidation. The rats were removed group by group 
from the experiment room, placed in plastic boxes, and taken 
to the supplementation room. This procedure was repeated 
daily at 02 PM since rodent have nocturnal habits and were less 
satiated at that time.
2.5 Determination of total hepatic lipid content
The determination of total hepatic lipid contents was done 
by the method of Bligh and Dyer (1959) with some modifications 
due to sample peculiarities. About 1 g of lyophilized sample 
was homogenized in 5 mL of chloroform, 10 mL of methanol, 
and 4 mL of water followed by continual rotary agitation for 
30 minutes. Next, 5 mL of chloroform and 5 mL of 1.5% sodium 
sulphate aqueous solution were added, and the sample was 
vigorously and continually shaken for 2 minutes. After dilution 
and complete separation of phases, the lower chloroform phase 
containing the lipids was filtered in quantitative paper filter to 
obtain a clear solution. From this phase, 2 mL were transferred 
(determination done in duplicate) to a previously weighed 
Petri dish, which was placed into an oven at 100 °C for solvent 
evaporation. After cooling in a desiccator, the dishes were 
weighed, and the total lipid percentage was calculated.
2.6 Sample preparation for examination by transmission 
electronic microscopy
Part of the liver left lobe of three rats per group (0.3 × 0.5 mm), 
randomly chosen, was excised and subjected to the protocols 
of fixing, post-fixing, dehydration, infiltration, inclusion, and 
contrasting by transmission electronic microscopy (TEM) 
visible by transmission electron microscopy (TEM) (BELURY; 
KEMPA-STECZKO, 1997; CHERIAN et al., 2002). Although 
CLA is naturally found in foods such as ruminant meat and 
dairy foods, the amounts are very small, and for that reason 
CLA is mainly consumed in the form of supplements. There 
are numerous commercial CLA mixtures in the market with 
different isomer proportions (but always with a predominance 
of cis-9, trans-11 and trans-10, and cis-12 isomers) and synthesis 
methods, which could influence physiological effects. The aim of 
this work was to assess the differences between two commercial 
CLA dietary supplementation in terms total lipid content of 
the liver and liver histology of the liver of healthy Wistar rats.
2 Materials and methods
2.1 Supplements
The investigated supplements were linoleic acid Sigma 
(code L 1376), the commercial conjugated linoleic acid 
mixtures AdvantEdge® CLA (EASTM, Golden, CO, USA), 
and CLA One® Free Fatty Acid Oil 1CLA1-FFBL-KG 
(Pharmanutrients, Gurnee, IL, USA). The isomers’ composition 
of conjugated linoleic acid supplements was determined by 
gas chromatography (SEHAT  et  al., 1998; SANTOS-ZAGO; 
BOTELHO; OLIVEIRA, 2007).
2.2 Animals and diets
The biological assays were conducted with albino male 
healthy recently-weaned Wistar rats aged 21 to 23 days, with 
mean weight 59.7 ± 5.84 g, obtained from the Multidisciplinary 
Center for Biological Investigation, State University of 
Campinas. During the assay, the animals remained in individual 
stainless steel growth cages, and received water and feed ad 
libitum. Temperature and humidity were kept in the range of 
22 e 23 °C and 60-70%, respectively, and a 12-hour light/dark 
cycle. This procedure was approved by the Ethics Commission 
on Animal Experimentation (CEEA - IB/Unicamp), Protocol 
no. 564-1. The diet, AIN93G, was prepared according to 
the American Society for Nutrition (REEVES; NIELSEN; 
FAHEY, 1993), with protein concentration of 12% (Table 1) 
(GOENA et al., 1989).
2.3 Experimental design
Thirty rats remained in a period of adjustment for 7 days 
receiving water and the respective diets ad libitum. After this 
period the animals were divided into 3 groups in order to 
achieve body weight homogeneity within and among the groups. 
Group C (control) received linoleic acid; group AE received 
AdvantEdge® CLA; and group CO received CLA One®. The 
supplement concentration was 2% of daily feed consumption. 
Animals were supplemented daily for 6 weeks. Body weight and 
feed consumption were determined every two days. At the end of 
the study, part of the liver left lobe was excised, weighed, frozen 
in liquid nitrogen, and stored at -80 °C before lyophilization for 
determination of total lipid content.
Table 1. Composition of experimental diet.
Ingredients g.kg-1
Cornstarch 430.796
Dextrinized cornstarch 143.060
Casein (81.5% protein) 147.230
Sucrose 108.370
Soybean oil 70.000
Fiber 50.000
Mineral mix 35.000
Vitamin mix 10.000
L-cystine 3.000
Choline bitartrate 2.500
Tert-butylhydroquinone 0.014
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groups. With regard to total hepatic lipids, no significant 
difference (p > 0.05) was observed between the control group 
and the groups receiving AdvantEdge® CLA or CLA One®
Figure 2a, b and c illustrate TEM liver images of animals 
that received supplementation of linoleic acid (group  C), 
AdvantEdge® CLA (group AE), and CLA One® (group CO)
(All images were analysed by technical staff from Laboratory 
of Food Microscopy (College of Food Engeneering) and from 
Electronic Microscopy Laboratory (Institute of Biology), both 
of the State University of Campinas). Those pictures show a 
large amount of small and long mitochondria spread between 
the rough and smooth endoplasmic reticulum in the central 
region of the cell and large and round-sahped mithocondria 
near the cell peripheral region, which characterizes cell integrity 
(SATO, 2004).
according to Yamasaki et al. (2000) with some adaptations based 
on the protocols of Haddad et al. (1998). After extraction, the 
samples were immediately fixed in a glutaraldehyde solution 
(2%) in cacodylate buffer (0.1 M, pH 7.3) for 2 hours at 4 °C. 
After this, the samples were washed in cacodylate buffer (3 times, 
for 10 minutes each) and subjected to the post-fixing procedure, 
remaining in osmium tetroxide in cacodylate buffer (0.2 M, pH 
7.3) for 2 extra hours at 4 °C. Before beginning the ethanol series 
dehydration, the samples underwent postfixation, in which they 
were washed 3 times for 10 minutes in a physiological solution 
added with sucrose (17.8%) and remained in an aqueous 
solution of uranyl acetate (0.5%) added with sucrose (13.3%) 
for 12 hours.
For the dehydration process, the samples were washed 
3 times for 15 minutes in an ethanol series of 50%, 70%, 90%, 95%, 
and 100% ending with two 15-minute washings in propylene 
oxide. The samples were then subjected to the procedures of 
infiltration and inclusion. After their inclusion in resin, the 
samples were sent to the Electronic Microscopy Laboratory of 
the Biology Institute of the State University of Campinas for 
ultrathin cuts (70 nm thickness), which were placed in copper 
meshes (3 mm / 200 mesh). The samples were contrasted in 
uranyl acetate solution (5%) in water for 20 minutes and in lead 
citrate solution (2.66 g of lead nitrate dissolved in 60 mL of water, 
3.52 g of sodium citrate and 32 mL of sodium hydroxide 1 N) 
for 5 minutes. After contrasting, the samples were examined in 
a transmission electronic microscope (LEO 906 Zeiss).
2.7 Statistical analysis
The results were expressed as means ± standard deviation. 
The data were analyzed statistically by ANOVA to test the effect 
of CLA mixtures. The effect of supplementation time on feed 
consumption and growth was also examined. The Tukey test 
was used to test the differences among the groups. Differences 
were considered significant at p < 0.05. The software used for 
all tests was Statistical Analysis System (2003).
3 Results
The total cis-9, trans-11 CLA and trans-10, cis-12 CLA of the 
commercial mixtures was 79.27% and 73.08% for AdvantEdge® 
CLA and CLA One®, respectively. The data of feed consumption, 
initial and final body weight and feed efficiency, are shown in 
Table 2 and Figure 1. Differences were found only between 
groups C and AE (p ≤ 0.05).
The results of the liver weight/body weight ratio were 
expressed in Table 3.There was no significant difference 
(p > 0.05) between the control group and CLA supplemented 
Table 2. Mean values ± standard deviation (n = 10) of feed consumption, initial and final body weight and feed efficiency of experimental and 
control groups over the six week intervention period.
Groups Consumption (g) Initial body weight (g) Final body weight (g) Feed efficiency
C 631.2 ± 48.7a 91.4 ± 2.3a 284.0 ± 20.2a 0.30 ± 0.02a
AE 645.7 ± 27.6b 96.3 ± 5.5a 299.8 ± 13.1a 0.31 ± 0.01a
CO 621.9 ± 30.9a. 96.7 ± 3.6a 283.7 ± 9.6a 0.30 ± 0.01a
Values not sharing similar letter in the same column are different (p ≤ 0.05) in the Tukey test. C: control; AE: group that received AdvantEdge® CLA; CO: group that received CLA One®.
Figure 1. Body weight (g) and food consumption (g/rat/period) in 
control and experimental groups (n = 10). Upper figure represents 
mean weight values (g); lower figure represents mean food consumption 
(g) in a period of two days during the period that animals remained 
in individual growth cages (38 days). C: control group; AE: group 
supplemented with AdvantEdge® CLA; CO: group supplemented with 
One® CLA; *statistical difference between group AE and group C and 
CO according to Tukey test (p ≤ 0.05).
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Table 3. Mean values ± standard deviation (n = 10) of liver lipid content and weight and liver weight: body weight rate of control and experimental 
groups.
Groups Lipid content % Liver weight g Liver weight: body weight rate
C 23.93 ± 3.64a 2.5 ± 0.4a 0.023 ± 0.03a
AE 22.19 ± 2.05a 2.8 ± 0.5a 0.025 ± 0.03a
CO 21.16 ± 0.90a 2.6 ± 0.3a 0.024 ± 0.02a
Values with diff erent letters in the same column indicate signifi cant diff erence (p < 0.05) in the Tukey test values expressed on a dry basis; lyophilized sample. C: control; AE: group 
that received AdvantEdge® CLA; CO: group that received CLA One®.
Figure 2. a)Hepatic Transmission Electron Microscopy (TEM) images 
of rats that received supplementation with linoleic acid; b) AdvantEdge® 
CLA; and c) CLA One®. Mi (mitochondria); Rer (rough endoplasmic 
reticulum); Gl (lipid globule).
Th is occurred cyclically throughout the assay, but it is 
important to note that these oscillations did not compromise 
animal growth.
As for the total hepatic lipid content, in the present work, 
no diff erence was found among all groups studied (p > 0.05). 
However, some studies reported lipid accumulation in the 
liver as a consequence of CLA supplementation. Studies 
on the infl uence of CLA on total hepatic lipid content have 
reported that this fatty acid accrue in the liver of experimental 
models, and this may result in the development of steatosis and 
non-alcoholic steatohepatitis (BELURY; KEMPA-STECZKO, 
1997; CHERIAN  et  al., 2002). Non-alcoholic steatohepatitis 
is so called when clinical and histopathological characteristics 
indicate steatohepatitis, but alcohol consumption has been 
ruled out as the cause. Th e designation was introduced in the 
1980s by Ludwig et al. (1980), but currently the preferred name 
is non-alcoholic fatty liver disease, which includes steatosis 
and steatosis accompanied by hepatitis (HOEK, 2004). Th e 
etiopathogenesis of this kind of hepatic lipid disease is related 
to the presence of a number of pathologic conditions such as 
obesity, diabetes, hyperlipidaemia, and oxidative stress. Th e 
latter has a double infl uence: direct, when oxidative stress 
itself causes liver damage; and indirect, when it activates an 
infl ammatory response leading to liver damage (BRUNT, 2001; 
CHITURI; FARREL, 2001; VIDELA  et  al., 2004; ADAMS; 
ANGULO; LINDOR, 2005).
Some researchers attempted to explain the appearance 
of steatosis and steatohepatitis by the determination of the 
expression of α and γ peroxisome proliferator activated 
receptors (PPAR α and PPAR γ). There is a hypothesis 
that CLA acts as a ligand of PPAR, especially PPAR α 
and PPAR γ (BELURY  et  al.,  2002; KANG  et  al., 2003; 
MOYA-CAMARENA et al., 1999). If this is indeed the case, 
CLA supplementation may be effi  cient in hepatic lipid disease 
prevention, and may act as an adjuvant in its treatment. 
Many physiological properties of CLA are explained by the 
inhibition or activation of the expression of these transcription 
factors. One of the earliest studies demonstrating that CLA 
activates PPAR was reported by Moya-Camarena et al. (1999). 
Th e results showed that CLA increases PPAR α expression, 
especially the cis-9 and trans-11 isomer. In 2002, Belury et al. 
(2002) stated that supplementation with CLA isomer mixture 
in kidney cells of monkeys stimulated PPAR γ activation. Th e 
activation of PPAR α and γ may be related to the increase in 
long and very long chain fatty acid oxidation. Th is is one of 
the explanations, for instance, of the eff ects of CLA on lipid 
profi le since the increase in fatty acid oxidation caused by the 
increased expression of PPAR α (AKBIYIK et al., 2004) could 
4 Discussion
With respect to the feed consumption and weight gain of 
the rats during the supplementation period, it can be said that 
even though small diff erences between some of the groups 
were observed, the animals growth was normal. Th ese feed 
consumption diff erences are a consequence of a correction in 
the supplementation amount for both, the control and CLA 
mixtures). Th e daily concentration of CLA supplementation 
was based on the daily feed consumption, i.e. the heavier the 
diet consumption, the heavier the supplement consumption. Th e 
lipidic origin of the supplement produced satiety, and therefore 
the diet consumption reduced and consequently the supplement 
consumption also reduced.
Diet consumption increase → supplement consumption 
increase; Diet consumption reduction (due to satiety) 
→ supplement consumption reduction.
Ciênc. Tecnol. Aliment., Campinas, 31(1): 141-146, jan.-mar. 2011144
Santos-Zago et al.
that consumed a diet with 1% of CLA for 80 days. More recently, 
Macarulla et al. (2005) investigated the effect of the trans-10, 
cis-12 and cis-9, and trans-11 isomers on hepatic histology of 
hamsters and did not find abnormalities in the organs after 
the animals consumed a diet supplemented with 0.5% of CLA 
isomers for 6 weeks.
Some researches assessed liver steatosis by monitoring 
the concentration of aminotransferases (LAVINE, 2000; 
ELITSUR  et  al., 2005); however, the histology assessment is 
the gold standard to evaluate the therapeutic efficacy against 
hepatic lipid disease of non-alcoholic origin. Akyüz et al. (2005) 
discussed the use of histology in order to assess the response 
of NASH to any therapy since they found no correlation 
between aminotransferase concentration and histology. In 
view of the above, enzymology could be a significant tool for 
the identification follow-up of non-alcoholic hepatic disease 
regression, but hepatic histology monitoring is necessary in 
this process since it can lead to different responses especially 
concerning the efficacy of therapies used to reverse the 
condition. 
5 Conclusions
After examining the results, it was concluded that the 
groups supplemented with conjugated linoleic acid did not 
display higher hepatic lipid content than the control group 
(p > 0.05). Although mean values did not indicate hepatic 
lipid accumulation, it was clearly observed that there was an 
increase of fat globules in the liver of rats that received CLA 
supplementation. However, this increase did not alter the 
histological pattern of cell organelles.
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